EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028

Lifesciences | Healthcare & Wellness

EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028

Market By Type, Industry Verticals, And Country | Forecast 2021-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton’s research report suggested that the European non-alcoholic steatohepatitis (NASH) biomarker market is appraised to garner a CAGR of 20.19% during the expected years of 2021-2028.


Report scope can be customized per your requirements. Request For Customization

The countries scrutinized in this market comprise:

        The UK

        Spain

        Germany

        Italy

        France

        Russia

        Rest of Europe

In the region, the surge in the prevalence of NASH, along with the rise in the geriatric population, is predicted to drive the progress of the examined market over the forecast period. Additionally, the increase in awareness pertaining to non-alcoholic fatty liver diseases and the rise in R&D activities to develop NASH therapeutics are augmenting the development of the non-alcoholic steatohepatitis biomarker market across Europe.

In Germany, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are essentially causing the development of cirrhosis and hepatocellular carcinoma. The country is likely to observe an increase in these diseases, owing to the rise in obesity, diabetes, and metabolic syndrome among the population. Further, there is a substantial rise in the obesity rates among children and adolescents, as stated by WHO. This high prevalence will eventually lead to the development of NASH and other conditions. All these factors are predicted to widen the scope of the NASH biomarker market in Germany in the next few years.

On the other hand, there is a surge in the number of clinical trials for non-alcoholic fatty liver disease in France. Although there are no specific drugs and diagnostics available in the market, they will likely enter the market in the upcoming years. Hence, the growing clinical trials are evaluated to positively impact the non-alcoholic steatohepatitis (NASH) biomarker market over the assessed period.

Genfit SA is a biopharmaceutical company involved in developing drugs and biomarkers in areas that lack effective treatments or diagnostic tools. It primarily focuses on its R&D activities to participate in the potential commercialization of treatment solutions to combat metabolic and inflammatory diseases, specifically affecting the liver. Among its products, elafibranor, a drug candidate, is currently evaluated under its phase 3 clinical trial to treat NASH. Genfit was founded in 1999 and is headquartered in France.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. KEY INSIGHTS

2.1.1. DEMAND FOR NASH BIOMARKERS

2.1.2. UNMET MEDICAL NEEDS

2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTE PRODUCTS

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR LANDSCAPE

2.6. KEY MARKET STRATEGIES

2.6.1. CONTRACTS & PARTNERSHIPS

2.6.2. BUSINESS EXPANSIONS & DIVESTITURES

2.6.3. ACQUISITIONS & MERGERS

2.6.4. NEW PRODUCT LAUNCHES

2.7. MARKET DRIVERS

2.7.1. RISING PREVALENCE OF NASH

2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES

2.8. MARKET RESTRAINTS

2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS

2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

2.9. MARKET OPPORTUNITIES

2.9.1. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE

3. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE

3.1. SERUM BIOMARKER

3.2. HEPATIC FIBROSIS BIOMARKER

3.3. APOPTOSIS BIOMARKER

3.4. OXIDATIVE STRESS BIOMARKER

3.5. OTHER TYPES

4. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS

4.1. PHARMA & CRO INDUSTRY

4.2. DIAGNOSTIC LAB

4.3. ACADEMIC RESEARCH KEY

4.4. HOSPITAL

5. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK

5.1. GERMANY

5.2. FRANCE

5.3. UNITED KINGDOM

5.4. ITALY

5.5. RUSSIA

5.6. SPAIN

5.7. REST OF EUROPE

6. COMPETITIVE LANDSCAPE

6.1. ALLERGAN

6.2. ASTRAZENECA

6.3. BRISTOL MYERS SQUIBB COMPANY

6.4. GENFIT SA

6.5. GILEAD SCIENCES INC

6.6. MADRIGAL PHARMACEUTICALS

6.7. MERCK & CO

6.8. NOVARTIS AG

6.9. NOVO NORDISK

6.10. PFIZER INC

6.11. SIEMENS HEALTHINEERS

6.12. VIKING THERAPEUTICS

6.13. ZYDUS CADILA

7. RESEARCH METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.1.1. OBJECTIVES OF STUDY

7.1.2. SCOPE OF STUDY

7.2. SOURCES OF DATA

7.2.1. PRIMARY DATA SOURCES

7.2.2. SECONDARY DATA SOURCES

7.3. RESEARCH METHODOLOGY

7.3.1. EVALUATION OF PROPOSED MARKET

7.3.2. IDENTIFICATION OF DATA SOURCES

7.3.3. ASSESSMENT OF MARKET DETERMINANTS

7.3.4. DATA COLLECTION

7.3.5. DATA VALIDATION & ANALYSIS

List of table

TABLE 1:       EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 2:       VENDOR LANDSCAPE

TABLE 3:       LIST OF CONTRACTS & PARTNERSHIPS

TABLE 4:       LIST OF BUSINESS EXPANSIONS & DIVESTITURES

TABLE 5:       LIST OF ACQUISITIONS & MERGERS

TABLE 6:       LIST OF NEW PRODUCT LAUNCHES

TABLE 7:       EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 8:       EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)

TABLE 9:       EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

List of Figures

FIGURE 1:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 2:     PORTER’S FIVE FORCES ANALYSIS

FIGURE 3:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)

FIGURE 4:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 5:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 6:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 7:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 8:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

FIGURE 9:     EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)

FIGURE 10:  EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

FIGURE 11:  EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

FIGURE 12:  EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

FIGURE 13:  EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

FIGURE 14:  GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 15:  FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 16:  UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 17:  ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 18:  RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 19:  SPAIN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

FIGURE 20:  REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;